CellCentric is initiating a clinical study of CCS1477, a first-in-class p300/CBP inhibitor, in haematological malignancies. CCS1477 is already in Phase I studies for late stage prostate cancer. The clinical programme is being extended to include acute myeloid leukaemia (AML), multiple myeloma (MM) and non-Hodgkin lymphoma (NHL) following new pre-clinical data showing profound anti-tumour effects of CCS1477 in models of these haematological malignancies. The Chief Investigator for the new Phase I/II clinical study will be Prof Andy Davies of University Hospital Southampton. The trial is expected to open for recruitment in Q2 2019.
CCS1477 is a novel, highly potent and specific inhibitor of the common bromodomain of two critical cancer regulatory proteins, p300 and CBP. The drug is formulated as a capsule to be taken orally. Inhibiting p300/CBP in blood cancers affects the IRF4-Myc pathway and can have a significant impact on tumour growth in pre-clinical models. CellCentric is now transitioning the product into haematological cancer clinical trials
CCS1477 is currently enrolling patients in
The clinical need and potential market for a new agent for late blood cancers
CellCentric will be presenting CCS1477 in the ‘New Drugs on the Horizon’ session at AACR in Atlanta, on the 31st March 2019.
CellCentric is a biotechnology company focused on a first-in-class p300/CBP bromodomain inhibitor drug, CCS1477. The company has investigated over 50 potential epigenetic-related drug targets, before focusing on the twin histone
CellCentric is a privately held business, with Morningside Venture Investments as its lead investor. CCS1477’s progress has also benefited from awards from Innovate UK (BioMedical Catalyst) and the Prostate Cancer Foundation. The company maintains active collaborations with multiple research centres in Europe and the US.